Compare CTRA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRA | VTRS |
|---|---|---|
| Founded | 1989 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 17.2B |
| IPO Year | 1994 | 2019 |
| Metric | CTRA | VTRS |
|---|---|---|
| Price | $34.58 | $13.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $35.27 | $13.50 |
| AVG Volume (30 Days) | ★ 10.2M | 8.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | 2.59% | ★ 3.52% |
| EPS Growth | ★ 49.33 | N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | $7,645,000,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $12.95 | $4.45 |
| Revenue Next Year | $7.21 | $1.79 |
| P/E Ratio | $15.13 | ★ N/A |
| Revenue Growth | ★ 40.07 | N/A |
| 52 Week Low | $22.33 | $6.85 |
| 52 Week High | $36.88 | $16.47 |
| Indicator | CTRA | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 43.46 |
| Support Level | $23.03 | $12.92 |
| Resistance Level | N/A | $13.49 |
| Average True Range (ATR) | 1.10 | 0.36 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 51.88 | 51.17 |
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.